Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope® for the treatment of adult patients with growth hormone deficiency

Paolo Beck-Peccoz, Francesco Minuto, Alfonso Leal-Cerro, Markus Zabransky, Günter Stalla

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: To describe the rationale and design of PATRO Adults, a postmarketing surveillance study of the long-term efficacy and safety of somatropin (Omnitrope®) for the treatment of adult patients with growth hormone deficiency (GHD).Methods: PATRO Adults is an observational, multicentre, open, longitudinal, noninterventional study being conducted in hospitals and specialized endocrinology clinics across several European countries. The primary objective is to assess the safety and efficacy of Omnitrope® in adults treated in routine clinical practice. Eligible patients are male or female adults who are receiving treatment with Omnitrope® and who have provided informed consent. Patients who have been treated with another human growth hormone (hGH) product before starting Omnitrope® therapy will also be eligible for inclusion. Efficacy assessments will be based on the analysis of the following: insulin-like growth factor-1 levels within age- and gender-adjusted normal ranges; anthropometric measures (weight, waist circumference, total fat mass, lean body mass, total body water); bone mineral density; lipids; effects on cardiovascular risk factors such as glucose metabolism, blood pressure and inflammatory markers (e.g. C-reactive protein); and quality of life. All adverse events will be monitored and recorded. Particular emphasis will be placed on long-term safety, the recording of malignancies, the occurrence and clinical impact of antirecombinant hGH antibodies, the incidence, severity and duration of hyperglycaemia, and the development of diabetes during treatment with Omnitrope®.Conclusions: PATRO Adults is a large, long-term, postmarketing surveillance study that will extend the safety database for Omnitrope®, as well as contributing to the available data for all recombinant hGH products. Of particular interest, the study will provide important data on the impact of long-term GH replacement therapy on the development of diabetes mellitus, the recurrence/regrowth of hypothalamic-pituitary tumours, and de novo malignancy or recurrence of other (non-hypothalamic-pituitary) tumours.

Original languageEnglish
Pages (from-to)85-91
Number of pages7
JournalTherapeutic Advances in Endocrinology and Metabolism
Volume3
Issue number3
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Human Growth Hormone
Growth Hormone
Multicenter Studies
Safety
Therapeutics
Pituitary Neoplasms
Hypothalamic Neoplasms
Recurrence
Body Water
Endocrinology
Waist Circumference
Somatomedins
Informed Consent
Hyperglycemia
C-Reactive Protein
Bone Density
Longitudinal Studies
Neoplasms
Diabetes Mellitus
Reference Values

Keywords

  • adults
  • growth hormone deficiency
  • human growth hormone
  • somatropin

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope® for the treatment of adult patients with growth hormone deficiency. / Beck-Peccoz, Paolo; Minuto, Francesco; Leal-Cerro, Alfonso; Zabransky, Markus; Stalla, Günter.

In: Therapeutic Advances in Endocrinology and Metabolism, Vol. 3, No. 3, 06.2012, p. 85-91.

Research output: Contribution to journalArticle

@article{c5b21acee48b428cbdf0190e2f6d2cc7,
title = "Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope{\circledR} for the treatment of adult patients with growth hormone deficiency",
abstract = "Objective: To describe the rationale and design of PATRO Adults, a postmarketing surveillance study of the long-term efficacy and safety of somatropin (Omnitrope{\circledR}) for the treatment of adult patients with growth hormone deficiency (GHD).Methods: PATRO Adults is an observational, multicentre, open, longitudinal, noninterventional study being conducted in hospitals and specialized endocrinology clinics across several European countries. The primary objective is to assess the safety and efficacy of Omnitrope{\circledR} in adults treated in routine clinical practice. Eligible patients are male or female adults who are receiving treatment with Omnitrope{\circledR} and who have provided informed consent. Patients who have been treated with another human growth hormone (hGH) product before starting Omnitrope{\circledR} therapy will also be eligible for inclusion. Efficacy assessments will be based on the analysis of the following: insulin-like growth factor-1 levels within age- and gender-adjusted normal ranges; anthropometric measures (weight, waist circumference, total fat mass, lean body mass, total body water); bone mineral density; lipids; effects on cardiovascular risk factors such as glucose metabolism, blood pressure and inflammatory markers (e.g. C-reactive protein); and quality of life. All adverse events will be monitored and recorded. Particular emphasis will be placed on long-term safety, the recording of malignancies, the occurrence and clinical impact of antirecombinant hGH antibodies, the incidence, severity and duration of hyperglycaemia, and the development of diabetes during treatment with Omnitrope{\circledR}.Conclusions: PATRO Adults is a large, long-term, postmarketing surveillance study that will extend the safety database for Omnitrope{\circledR}, as well as contributing to the available data for all recombinant hGH products. Of particular interest, the study will provide important data on the impact of long-term GH replacement therapy on the development of diabetes mellitus, the recurrence/regrowth of hypothalamic-pituitary tumours, and de novo malignancy or recurrence of other (non-hypothalamic-pituitary) tumours.",
keywords = "adults, growth hormone deficiency, human growth hormone, somatropin",
author = "Paolo Beck-Peccoz and Francesco Minuto and Alfonso Leal-Cerro and Markus Zabransky and G{\"u}nter Stalla",
year = "2012",
month = "6",
doi = "10.1177/2042018812444152",
language = "English",
volume = "3",
pages = "85--91",
journal = "Therapeutic Advances in Endocrinology and Metabolism",
issn = "2042-0188",
publisher = "Sage Periodicals Press",
number = "3",

}

TY - JOUR

T1 - Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope® for the treatment of adult patients with growth hormone deficiency

AU - Beck-Peccoz, Paolo

AU - Minuto, Francesco

AU - Leal-Cerro, Alfonso

AU - Zabransky, Markus

AU - Stalla, Günter

PY - 2012/6

Y1 - 2012/6

N2 - Objective: To describe the rationale and design of PATRO Adults, a postmarketing surveillance study of the long-term efficacy and safety of somatropin (Omnitrope®) for the treatment of adult patients with growth hormone deficiency (GHD).Methods: PATRO Adults is an observational, multicentre, open, longitudinal, noninterventional study being conducted in hospitals and specialized endocrinology clinics across several European countries. The primary objective is to assess the safety and efficacy of Omnitrope® in adults treated in routine clinical practice. Eligible patients are male or female adults who are receiving treatment with Omnitrope® and who have provided informed consent. Patients who have been treated with another human growth hormone (hGH) product before starting Omnitrope® therapy will also be eligible for inclusion. Efficacy assessments will be based on the analysis of the following: insulin-like growth factor-1 levels within age- and gender-adjusted normal ranges; anthropometric measures (weight, waist circumference, total fat mass, lean body mass, total body water); bone mineral density; lipids; effects on cardiovascular risk factors such as glucose metabolism, blood pressure and inflammatory markers (e.g. C-reactive protein); and quality of life. All adverse events will be monitored and recorded. Particular emphasis will be placed on long-term safety, the recording of malignancies, the occurrence and clinical impact of antirecombinant hGH antibodies, the incidence, severity and duration of hyperglycaemia, and the development of diabetes during treatment with Omnitrope®.Conclusions: PATRO Adults is a large, long-term, postmarketing surveillance study that will extend the safety database for Omnitrope®, as well as contributing to the available data for all recombinant hGH products. Of particular interest, the study will provide important data on the impact of long-term GH replacement therapy on the development of diabetes mellitus, the recurrence/regrowth of hypothalamic-pituitary tumours, and de novo malignancy or recurrence of other (non-hypothalamic-pituitary) tumours.

AB - Objective: To describe the rationale and design of PATRO Adults, a postmarketing surveillance study of the long-term efficacy and safety of somatropin (Omnitrope®) for the treatment of adult patients with growth hormone deficiency (GHD).Methods: PATRO Adults is an observational, multicentre, open, longitudinal, noninterventional study being conducted in hospitals and specialized endocrinology clinics across several European countries. The primary objective is to assess the safety and efficacy of Omnitrope® in adults treated in routine clinical practice. Eligible patients are male or female adults who are receiving treatment with Omnitrope® and who have provided informed consent. Patients who have been treated with another human growth hormone (hGH) product before starting Omnitrope® therapy will also be eligible for inclusion. Efficacy assessments will be based on the analysis of the following: insulin-like growth factor-1 levels within age- and gender-adjusted normal ranges; anthropometric measures (weight, waist circumference, total fat mass, lean body mass, total body water); bone mineral density; lipids; effects on cardiovascular risk factors such as glucose metabolism, blood pressure and inflammatory markers (e.g. C-reactive protein); and quality of life. All adverse events will be monitored and recorded. Particular emphasis will be placed on long-term safety, the recording of malignancies, the occurrence and clinical impact of antirecombinant hGH antibodies, the incidence, severity and duration of hyperglycaemia, and the development of diabetes during treatment with Omnitrope®.Conclusions: PATRO Adults is a large, long-term, postmarketing surveillance study that will extend the safety database for Omnitrope®, as well as contributing to the available data for all recombinant hGH products. Of particular interest, the study will provide important data on the impact of long-term GH replacement therapy on the development of diabetes mellitus, the recurrence/regrowth of hypothalamic-pituitary tumours, and de novo malignancy or recurrence of other (non-hypothalamic-pituitary) tumours.

KW - adults

KW - growth hormone deficiency

KW - human growth hormone

KW - somatropin

UR - http://www.scopus.com/inward/record.url?scp=84861445003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861445003&partnerID=8YFLogxK

U2 - 10.1177/2042018812444152

DO - 10.1177/2042018812444152

M3 - Article

C2 - 23148199

AN - SCOPUS:84861445003

VL - 3

SP - 85

EP - 91

JO - Therapeutic Advances in Endocrinology and Metabolism

JF - Therapeutic Advances in Endocrinology and Metabolism

SN - 2042-0188

IS - 3

ER -